Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Earnings

Review historical estimates and see whether a company has beaten or missed expectations.

Last Close
Jul 17 04:00PM ET
Dollar change
Percentage change
IndexRUT P/E- EPS (ttm)-2.65 Insider Own10.33% Shs Outstand12.82M Perf Week14.99%
Market Cap575.53M Forward P/E- EPS next Y-4.25 Insider Trans0.00% Shs Float11.64M Perf Month4.11%
Income-39.03M PEG- EPS next Q-1.05 Inst Own83.66% Short Float9.19% Perf Quarter25.97%
Sales0.00M P/S- EPS this Y-241.49% Inst Trans-32.38% Short Ratio9.35 Perf Half Y37.28%
Book/sh13.28 P/B3.34 EPS next Y-2.50% ROA-26.57% Short Interest1.07M Perf Year139.68%
Cash/sh13.06 P/C3.39 EPS next 5Y25.10% ROE-30.96% 52W Range12.20 - 53.00 Perf YTD128.79%
Dividend Est.- P/FCF- EPS past 5Y-16.09% ROI-21.39% 52W High-16.34% Beta1.47
Dividend TTM- Quick Ratio14.74 Sales past 5Y-20.00% Gross Margin- 52W Low263.44% ATR (14)3.52
Dividend Ex-Date- Current Ratio14.74 EPS Y/Y TTM-143.04% Oper. Margin0.00% RSI (14)63.00 Volatility10.14% 10.50%
Employees91 Debt/Eq0.08 Sales Y/Y TTM- Profit Margin- Recom1.14 Target Price51.80
Option/ShortNo / Yes LT Debt/Eq0.07 EPS Q/Q-290.56% Payout- Rel Volume1.80 Prev Close45.75
Sales Surprise- EPS Surprise3.29% Sales Q/Q- EarningsMay 10 BMO Avg Volume114.38K Price44.34
SMA2020.27% SMA5024.19% SMA20057.45% Trades Volume206,186 Change-3.08%
Date Action Analyst Rating Change Price Target Change
Jun-27-24Initiated BMO Capital Markets Outperform $65
Jun-11-24Initiated Robert W. Baird Outperform $54
Apr-29-24Initiated Leerink Partners Outperform $46
Mar-21-24Initiated William Blair Outperform $61
Jan-08-24Initiated H.C. Wainwright Buy $45
Jan-05-24Initiated Stifel Buy $31
Jan-04-24Initiated TD Cowen Outperform
Jul-02-24 07:30AM
Jul-01-24 07:30AM
Jun-19-24 09:23AM
Jun-18-24 09:26AM
Jun-05-24 07:30AM
07:30AM Loading…
Jun-03-24 07:30AM
May-10-24 01:54PM
May-07-24 06:19AM
Apr-22-24 04:36PM
Mar-20-24 05:31AM
Mar-18-24 04:14PM
Mar-04-24 07:30AM
Feb-29-24 07:30AM
Jan-16-24 07:00AM
07:00AM Loading…
Jan-05-24 07:00AM
Dec-19-23 07:00AM
Neurogene, Inc. is a clinical-stage biotechnology company, which engages in the development of product portfolio of genetic medicines for rare neurological diseases. The company was founded in May 2007 and is headquartered in New York, NY.